GRAL

Over the past six months, GRAIL completed a $110 million equity financing with Samsung entities on June 25, 2026. Priority Health announced a collaboration with GRAIL on July 16, 2026, becoming the first Michigan health plan to offer the Galleri test to employer plans. The company reported its Second Quarter 2026 financial results on August 5, 2026, and announced an upcoming FDA Advisory Committee Meeting for Galleri's Premarket Approval (PMA) application on August 7, 2026. At the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, GRAIL highlighted its commercial momentum and the urgency of regulatory processes. On September 23, 2026, the FDA's Molecular and Clinical Genetics Devices Panel voted favorably for Galleri's PMA application, supporting its safety, effectiveness, and overall benefit-risk profile, which led to a significant stock price surge of approximately 80% in the month leading up to October 11, 2026, with trading halted prior to the meeting. GRAIL announced on October 5, 2026, that it would present new data from the NHS-Galleri and PATHFINDER 2 studies at the EDCC and ESMO Congress 2026. On October 7, 2026, the company's CFO and growth chief sold shares to cover vesting taxes, part of other insider selling activity in September and October 2026 for the same reason. Overall, GRAIL's stock price gained 82.2% over the past 12 months, trading at $132.61 on October 8, 2026, up from $85.59 at the start of the year.